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Abstract
Several recent studies have demonstrated that endothelial to mesenchymal transition (EndoMT), a newly
recognized type of cellular transdifferentiation may be an important source of myofibroblasts during the
development of experimentally induced pulmonary, cardiac and kidney fibrosis. EndoMT is a complex biological
process induced by members of the transforming growth factor (TGF-b) family of regulatory polypeptides in which
endothelial cells adopt a mesenchymal or myofibroblastic phenotype acquiring motile and contractile properties
and initiating expression of mesenchymal cell products such as a smooth muscle actin (a-SMA) and type I
collagen. Although these experimental studies provide compelling evidence for the participation of EndoMT in the
development of experimentally-induced fibrotic processes the precise role of EndoMT in the pathogenesis of
human fibrotic disorders requires confirmation and validation from studies of human clinical pathologic conditions.
Such confirmation should lead to a change in the paradigm of the origin of profibrogenic myofibroblasts involved
in human fibrotic diseases. Further understanding of the molecular mechanisms and the regulatory pathways
involved in EndoMT may lead to the development of novel therapeutic approaches for the incurable and often
devastating fibrotic disorders.
Introduction
It is generally accepted that activated mesenchymal cells
or myofibroblasts play a crucial role in the pathogenesis
of various fibrotic diseases including interstitial pulmon-
ary fibrosis, systemic sclerosis and liver or cardiac fibrosis
being responsible for the exaggerated production and
accumulation of extracellular matrix proteins in various
organs affected by these diseases [1-4]. Although the etio-
logic factors that initiate the fibrotic diseases are diverse
and in most instances remain unknown, the accumula-
tion of activated myofibroblasts in affected tissues and
the persistence of their elevated biosynthetic functions
are crucial determinants of the severity and rate of pro-
gression of these diseases, and of their clinical course,
response to therapy, prognosis, and mortality. Thus, a
precise understanding of the origin of these cells and of
the mechanisms involved in the regulation of their intri-
cate functions are of paramount importance for the
development of effective therapeutic approaches for the
vast spectrum of disorders associated with tissue and
organ fibrosis [5,6]. Myofibroblasts in the fibrotic diseases
are derived from at least three sources: 1) expansion and
activation of resident tissue fibroblasts [7,8]; 2) transition
of epithelial cells into mesenchymal cells, a process
known as epithelial-mesenchymal transition [9-14]; and
3) tissue migration of bone marrow-derived circulating
fibrocytes [15,16]. Recently, endothelial to mesenchymal
transition (EndoMT), a newly recognized type of cellular
transdifferentiation [17], has emerged as another possible
source of tissue myofibroblasts which may play a crucial
role in the pathogenesis of fibrotic diseases [18,19].
EndoMT is a complex biological process in which
endothelial cells lose their specific endothelial cell mar-
kers, such as vascular endothelial (VE) cadherin, and
acquire a mesenchymal or myofibroblastic phenotype
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initiating expression of mesenchymal cell products
including a-smooth muscle actin (a-SMA), vimentin,
and types I and III interstitial collagens. Besides acquisi-
tion of an activated pro-fibrogenic phenotype these cells
also become motile and are capable of migrating into
surrounding tissues. Although in the past EndoMT was
believed to be a rare phenomenon confined to certain
stages of embryonic development [17,20] its occurrence
in fibrotic disorders is gaining increased attention.
Indeed, multiple antibody immunofluorescence confocal
microscopy studies and endothelial cell lineage analyses
during the development of various experimentally-
induced animal models of tissue fibrosis have demon-
strated the participation of EndoMT in the pathogenesis
of fibrotic processes in various organs [21-26]. Although
numerous studies have examined the role of epithelial
mesenchymal transition (EMT) in the pathogenesis of
fibrotic disorders [27] and there has been extensive inves-
tigation of the molecular events responsible for this pro-
cess [28-31], studies examining the mechanisms involved
in EndoMT and its potential participation in pathologic
tissue fibrosis in human diseases are limited.
EndoMT in experimentally-induced organ fibrosis
The occurrence of EndoMT in experimentally induced
cardiac fibrosis was originally described by Zeisberg et al.
[21] employing endothelial cell lineage analysis in trans-
genic mice. In these studies, analyses of the proportion of
fibroblasts present in the fibrotic myocardium of mice
with aortic banding induced myocardial fibrosis showed
that from 27 to 35% of fibroblasts originated from
endothelial cells. Several other studies have confirmed
the emergence of activated fibroblasts originating from
endothelial cells in various experimentally induced mod-
els of cardiac fibrosis [22,23] and collectively have sug-
gested that in these experimental conditions EndoMT
represents an important contributor to the generation of
fibrotic tissue and, therefore, this pathway may represent
a novel therapeutic target. EndoMT has also emerged as
a potentially important mechanism in the development
and progression of experimentally induced pathological
kidney and pulmonary fibrosis. Numerous studies have
shown that EndoMT is a novel pathway leading to fibro-
tic development in diabetic nephropathy and other mod-
els of kidney fibrosis. An extensive study by Zeisberg et
al. [24] examined the role of EndoMT in three murine
models of chronic kidney disease: unilateral ureteral
obstructive nephropathy, streptozotocin-induced diabetic
nephropathy and a model of Alport renal disease. The
results of these studies indicated that 30-50% of myofi-
broblasts in the fibrotic kidneys, identified by their
expression of a fibroblast phenotype and a-SMA, display
the endothelial cell specific CD31 surface marker indicat-
ing their endothelial cell origin. These studies were
validated by endothelial cell lineage tracing and were also
confirmed by studies from other laboratories [18,25]. The
possible role of EndoMT in experimentally induced pul-
monary fibrosis was examined by Hashimoto et al. [26].
These authors evaluated EndoMT as a source of intersti-
tial fibroblasts in bleomycin-induced lung fibrosis using
double-transgenic mice in which LacZ was stably
expressed in endothelial cells and therefore allowed the
histological identification of any cells originated from an
endothelial cell lineage. Following endotracheal injection
of bleomycin the areas of fibrotic involvement were
shown to contain large numbers of fibroblasts of
endothelial origin. To directly demonstrate the presence
of endothelial cell-derived lung fibroblasts in affected
lung fibrotic tissues, lung fibroblasts were isolated and
cultured from either saline injected control mice or from
mice that received bleomycin injections. These studies
revealed that approximately 16% of lung fibroblasts in
the cultures from bleomycin-treated mice were derived
from endothelial cells as illustrated in Figure 1.
EndoMT of human endothelial cells
In contrast with the extensive evidence from experimen-
tal animal models demonstrating the important participa-
tion of EndoMT in the development of tissue fibrosis
studies with human endothelial cells are just beginning
to appear. One such study [32] examined the conversion
of human microvascular intestinal endothelial cells into
mesenchymal cells following exposure to a combination
of proinflammatory cytokines (TGF-b, TNF-a and IL-1b)
in vitro. The treated cells displayed a progressive loss and
the eventual disappearance of endothelial-specific cell
markers (CD-31 and VE-cadherin) and a parallel acquisi-
tion of mesenchymal cell markers including vimentin,
collagen I and N-cadherin. These results suggested that
intestinal endothelial cells exposed to an inflammatory
environment may participate in the intestinal fibrotic
process which accompanies intestinal inflammatory dis-
eases. The in vitro observations were confirmed by stu-
dies of molecular co-localization in human colonic
mucosa [32].
Another study examined the expression of cell surface
markers specific for endothelial cells in mesenchymal/
fibroblastic cells present in the subendothelial compart-
ment of small vessels in lungs from patients with Sys-
temic Sclerosis-associated pulmonary fibrosis [33].
Confocal microscopy demonstrated the expression of
endothelial cell markers (CD-31 and CD-34) in mesench-
ymal cells embedded within the subendothelial neointima
of small pulmonary arteries in lung specimens from
patients with Systemic Sclerosis. These two studies pro-
vide strong support to the concept that EndoMT may
also play an important role in the pathogenesis of human
fibrotic diseases.
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Molecular Mechanisms of EndoMT
In contrast to the very extensive studies conducted to
unravel the molecular mechanisms and the regulatory
pathways that modulate epithelial mesenchymal transi-
tion [27-31], the mechanisms involved in the EndoMT
process have not been explored in detail. Few studies
have examined the biochemical and molecular changes
occurring in endothelial cells during their transdifferen-
tiation into mesenchymal myofibroblasts and the regula-
tory events involved in this process. It is generally
accepted that TGF-b plays a crucial role in tissue fibrosis
and is implicated in the pathogenesis of numerous fibro-
tic disorders [5,6,34-37]. Recent studies have shown that
besides causing a potent stimulation of the expression of
numerous genes participating in the fibrotic process,
TGF-b is involved in the generation of myofibroblasts
through EndoMT [21,22,38-42]. The studies in experi-
mentally induced cardiac hypertrophy provided an ele-
gant demonstration of the role of TGF-b in this process
[21]. These studies showed that TGF-b was a crucial
mediator causing endothelial cells to undergo EndoMT
since there was a significant reduction in the number of
mesenchymal cells originating from endothelial cells
when the TGF-b response was blunted by the deficiency
of Smad3 in Smad 3+/- transgenic mice. These results
have been confirmed employing a TGF-b receptor kinase
inhibitor which inhibits activated TGF-b [40] as well as
several small molecule inhibitors of intracellular phos-
phorylation reactions [41,42].
Besides TGF-b it has been shown that endothelin-1 (ET-
1) may also participate in EndoMT. In one study, Widyan-
toro et al. [23] showed that endothelial cell-derived ET-1
promotes cardiac fibrosis and heart failure in diabetic hearts
through stimulation of EndoMT. These features were abol-
ished in hearts from transgenic mice with endothelial cell
specific ET-1 deletion. In another study it was shown that
in vitro treatment of murine pulmonary endothelial cells
with ET-1 although not capable of initiating EndoMT by
Figure 1 Demonstration of endothelial cell-derived fibroblasts in fibroblast cultures established from lung parenchyma of mice with
bleomycin induced pulmonary fibrosis. Fibroblast cultures were established from lungs from mice injected intratrachealy with either normal
saline or bleomycin. When the cultures reached confluency they were stained with x-gal to identify the cells from endothelial lineage. Note the
absence of x-gal staining cells in the cultures from saline injected control mice (A) in contrast with the marked abundance of x-gal staining
fibroblasts in the cultures from bleomycin injected mice (B). The inset in A shows the percentage of x-gal positive cells in four separate samples
of cultured fibroblasts from saline injected mice (SLF) compared to eight separate samples of fibroblasts cultured from bleomycin injected mice
(BLF). Figures C and D show sequential staining of a fibroblast culture from bleomycin injected mice with x-gal (C) followed by
immunocytochemistry for the mesenchymal cell markers type I collagen (red) and a- SMA (green). The arrows indicate cells positive for x-gal,
type I collagen, and a- SMA, whereas the arrowheads indicate cells positive for x-gal and type I collagen. Reproduced from reference 26 with
permission.
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itself could excert a powerful synergistic effect with TGF-b
(Li and Jimenez; unpublished observations).
Although there are numerous studies which have con-
clusively shown the crucial involvement of members of
the TGF-b family of growth factors in initiation of
EndoMT, the detailed molecular events and the intracellu-
lar cascades activated by TGF-b that result in the remark-
able phenotypic change of endothelial cells to
mesenchymal cells have not been entirely elucidated.
Recent studies in primary cultures of murine pulmonary
endothelial cells [41] and in cultured human dermal
microvascular cells [42] demonstrated that EndoMT
involves both Smad-dependent and Smad-independent
pathways. The downstream signaling pathway initiated by
TGF-b resulted in strong upregulation of the transcrip-
tional repressor Snail1. Snail1 causes potent inhibition of
E-cadherin gene transcription in cultured cells and plays
an important role in the epithelial to mesenchymal transi-
tion [27,28] indicating that the EndoMT process shares
similar molecular mechanisms with epithelial mesenchy-
mal transdifferentiation.
Several studies explored the underlying molecular
pathways that may cause the significant loss of endothe-
lial-specific markers while inducing strong de novo
mesenchymal phenotypes. These studies identified the
c-Abl protein kinase (c-Abl), protein kinase Cδ (PKC-δ),
and glycogen synthase kinase 3b (GSK-3b) as important
participants and that GSK-3b kinase phosphorylation was
a crucial event in this process [41,42]. It is well known
that phosphorylation of specific serine residues in GSK-
3b results in inactivation of the kinase which in turn
induces the nuclear accumulation of Snail1 followed by a
profound increase in the expression of its corresponding
gene. The transcriptional effects of Snail1 induce the
expression of a mesenchymal cell-specific phenotype
although the precise mechanisms involved remain
obscure. In contrast, in the absence of GSK-3b phosphor-
ylation the GSK-3b kinase is active and induces the pro-
teosomal degradation of Snail1, thus abrogating the
acquisition by endothelial cells of a mesenchymal cell
phenotype. Other studies have shown that several impor-
tant regulatory pathways including the canonical Wnt
pathway, the HIF-1a hypoxia induced pathway, and the
response to cellular stress may also participate in the reg-
ulation of EndoMT [43,44] as illustrated in Figure 2.
In summary, numerous recent studies have provided
strong evidence for the prominent participation of
EndoMT in the generation of activated myofibroblasts
during the development of experimentally induced tissue
fibrosis suggesting that EndoMT plays a crucial role in
fibrotic diseases. There is some early experimental evi-
dence providing support and validation for the participa-
tion of EndoMT in the development of human intestinal
fibrosis and of Systemic Sclerosis-associated pulmonary
fibrosis. The firm demonstration of the occurrence of
EndoMT in human fibrotic diseases and further under-
standing of the molecular mechanisms involved may
lead to the pharmacologic modulation or abrogation of
this pathway in human fibrotic disorders and may repre-
sent a novel therapeutic approach for these devastating
diseases.
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